The Butantan Institute of Brazil managed to generate a vaccine that prevents dengue with a general efficacy of 79.6%; For those who had not had previous exposure to the virus that causes this disease (or did not know if they had), the efficacy was 73.6%, and for those who did have a history of exposure, 89.2% after two years of follow-up in all age groups.
It is expected that this vaccine can cover the need for a vaccine against dengue that offers protection with a single dose in a wide range of agesregardless of whether or not the person has been infected with this virus that is transmitted by the bite of mosquitoes of the genus Aedes.
At the moment There are two other tetravalent vaccines, live and attenuated, against dengue.. One is Sanofi Pasteur’s Dengvaxia (CYD-TDV), a three-dose derivative, authorized in several countries but which appears to imply “an increased risk of severe dengue after vaccination in people without a history of dengue infection,” the team notes. of Butantan (this risk became known in Mexico) .
Takeda’s Qdenga (TAK-003), a two-dose dengue vaccine derived from type 2 of this virus, was recently approved in Indonesia, the European Union and Brazil.
Butantan-DV meets the conditions
According to the results of a phase 3 trial in which 16,235 people participated in Brazil, which were published yesterday in it New England Journal of Medicine, The vaccine designed at the Butantan Institute is a live attenuated virus and is quadrivalent.that is, it is made against the four types of virus that cause dengue.
The research team notes that since there were no cases of dengue caused by serotypes 3 or 4, It is not possible to know the effectiveness of the vaccine against them; It also reports that there were more reports of discomfort and side effects in those who received the biological than in those who were injected with a placebo.
Mexico, third place in cases in LA
The Pan American Health Organization (PAHO) reported recently that 2023 is the year with the highest historical record of dengue casesexceeding 4.1 million new infections globally, which far exceeded the 3.1 million cases in 2019, and which included 28,203 serious cases and 1,823 deaths.
The highest number of dengue cases in 2023 was observed in Brazil with two million 909 thousand 404 cases reported. In Latin America, Peru followed, with 269,603 cases, and Mexico with 216 thousand 277 cases. The incidence in the country, along with Central America, is 260 cases per one hundred thousand inhabitants.
KEEP READING |
Bangladesh records its worst dengue epidemic
Alert: Dengue
2024-02-10 12:01:44
#Brazil #effective #vaccine #dengue
